See more : Quartix Technologies Plc (QTX.L) Income Statement Analysis – Financial Results
Complete financial analysis of Peridot Acquisition Corp. (PDAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Peridot Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
- Atlantica, Inc. (ALDA) Income Statement Analysis – Financial Results
- Radium Development Berhad (5313.KL) Income Statement Analysis – Financial Results
- MEG Energy Corp. (MEG.TO) Income Statement Analysis – Financial Results
- Noritz Corporation (NRTZF) Income Statement Analysis – Financial Results
- CYBERDYNE Inc. (7779.T) Income Statement Analysis – Financial Results
Peridot Acquisition Corp. (PDAC)
About Peridot Acquisition Corp.
Peridot Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company was founded in 2020 and is based in Houston, Texas.
Metric | 2020 |
---|---|
Revenue | 0.00 |
Cost of Revenue | 0.00 |
Gross Profit | 0.00 |
Gross Profit Ratio | 0.00% |
Research & Development | 0.00 |
General & Administrative | 0.00 |
Selling & Marketing | 0.00 |
SG&A | 0.00 |
Other Expenses | -386.57K |
Operating Expenses | -386.57K |
Cost & Expenses | -386.57K |
Interest Income | 0.00 |
Interest Expense | 0.00 |
Depreciation & Amortization | 206.30K |
EBITDA | -386.57K |
EBITDA Ratio | 0.00% |
Operating Income | -386.57K |
Operating Income Ratio | 0.00% |
Total Other Income/Expenses | 0.00 |
Income Before Tax | -386.57K |
Income Before Tax Ratio | 0.00% |
Income Tax Expense | 0.00 |
Net Income | -386.57K |
Net Income Ratio | 0.00% |
EPS | -0.01 |
EPS Diluted | -0.01 |
Weighted Avg Shares Out | 37.50M |
Weighted Avg Shares Out (Dil) | 37.50M |
Tactile Medical's Shares Rise After PDAC Approval for Nimbl
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer
Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer
LICY FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors to Secure Counsel Before Important June 21 Deadline in Securities Class Action Filed by the Firm - LICY, PDAC
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. (LICY, PDAC) Investors of Class Action and Last Few Hours to Actively Participate
LICY TUESDAY DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors to Secure Counsel Before Important June 21 Deadline in Securities Class Action Initiated by the Firm - LICY, PDAC
LICY FINAL DEADLINE NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors with Losses to Secure Counsel Before Important June 21 Deadline in Securities Class Action Filed by the Firm - LICY, PD
ROSEN, A TOP RANKED LAW FIRM, Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors with Losses to Secure Counsel Before Important June 20 Deadline in Securities Class Action Filed by the Firm - LICY, PDAC
NATIONALLY RANKED ROSEN LAW FIRM Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors with Losses to Secure Counsel Before Important June 20 Deadline in Securities Class Action Filed by the Firm - LICY, PDAC
Source: https://incomestatements.info
Category: Stock Reports